- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
486
the receptive field. Since electrophysiological recordings were made in the superficial layer of the tectum and the extracellular multiunit recordings were generated in the area of the receptive field, we are confident that recordings were acquired from the terminal areas of the optic axons. We must therefore assume that optic axonal terminal arbors increase to cover larger than the normal terminal area of the tectum. We have recently observed (unpublished preliminary data) a qualitative increase in the optic axonal terminal areas in the tectum of glaucomatous animals when compared to the terminal areas (of similar type) seen on the mirror image location of contralateral normal tectum.
Behavioral consequences of glaucoma
Sauve et al. (2004) reported a reasonable correlation of full-field ERG and visual field thresholds recorded from the superior colliculus in rat. These authors showed that magnitude of b-wave could be used to predict the computed area and degree of visual field preservation in the central nervous system (CNS). Grozdanic et al. (2003) reported a similarly functional characterization of retina after ischemia. By contrast, a smaller number of studies have been undertaken to measure changes in visual function after glaucoma treatment (Greve et al., 1975; Flammer and Drance, 1983; Yoshikawa et al., 1989; Rolando et al., 1991). These authors showed moderate improvements in retinal function in humans. However, in animals with experimental glaucoma, hardly any studies have dealt with RGC survival and recovery of function. In rodent’s glaucoma, functional analysis has been hampered due to limited and tedious methodologies to test visual behavior. Recently, Prusky and his colleagues have developed a rapid quantification method for testing spatial vision in rats. The spatial vision (grating acuity and contrast sensitivity) can be measured by a virtual reality optomotor system in which spatial visual thresholds can be measured rapidly and without specific reinforcement training. The profiles of acuity and
contrast sensitivity present a dynamic picture of the functioning of the visual system, and the ability of the rat to reflexively track a moving grating can easily be assessed. Using this procedure, one can characterize the loss of vision in glaucomatous animals and evaluate the effects of various manipulations aimed at saving RGC in glaucoma. The other complimentary aspect of vision is the measurement of visual perceptual thresholds that can be used to follow changes in visual processing in glaucoma. The perceptual threshold is measured by visual water task method. Both tests are necessary to evaluate potential assessment of visual dysfunction.
Slow horizontal head and body rotation occurs in rats when the visual field is rotated around them. These optomotor responses can be readily produced. If one eye is closed, only motion in the temporal-to-nasal direction for the contralateral eye evokes the tracking response. When the maximal spatial frequency capable of driving the response (acuity) was measured under monocular and binocular viewing conditions, the monocular acuity was identical to binocular acuity measured with the same rotation direction. Thus, the visual capabilities through each eye can be measured under binocular conditions simply by changing the direction of rotation. The spatial frequency, contrast, and velocity of stimulus pattern are generated by the computer and can be changed instantaneously.
The grating thresholds of Long-Evans rats are clustered around 1.0 cycle/degree. Using spatial frequencies already described for Long-Evans rats (Prusky et al., 2002), visual thresholds were obtained in normal rat. As described by Prusky et al. (2000), for each eye, motion in the temporal- to-nasal direction evokes tracking, whereas motion in the nasal-to-temporal direction does not. We used frequency of 0.103 cycle/degree sine wave gratings. As grating was rotated, rat ceased body movements and began to track grating with head movements in relation to the rotation. The contrast was increased or decreased to achieve the threshold. In experimental animals where only one eye had elevated IOP and the contralateral eye served as a control, the tests for contrast sensitivity and visual acuity began at 5 weeks after the
surgery. The mean IOP of the control left eye was 16.5 mmHg, whereas the experimental right eye had a mean IOP of 25.15 mmHg. Visual acuity refers to the maximal spatial frequency that evoked an optomotor response. Acuity thresholds were measured for both eyes of normal and experimental animals in which one eye had elevated IOP. The eyes of normal animals had comparable mean acuity thresholds of 0.52; a paired t-test indicates no significant difference between the eyes of normal animals (t ¼ 1, df ¼ 2, p ¼ 0.42). For elevated IOP eyes, the experimental eye had a lower mean acuity value (0.1570.013 SEM) than did the contralateral normal eye (0.5270.001 SEM). A paired t-test indicated that the acuity values for the experimental and normal eye differed significantly (t ¼ 26.9, df ¼ 6, po0.0005).
These animals were further tested for contrast sensitivity as a function of spatial frequency. The experiment formed a 2 6 design (eye vs. spatial frequency) with repeated measures on both variables. A 2 6 repeated-measures ANOVA indicated that the main effect of eye (normal vs. experimental elevated IOP eye) was significant (f ¼ 22, 471.6, df ¼ 1, po0.0005).
487
The main effect of spatial frequency was also significant (f ¼ 626.7, df ¼ 5, po0.0005). Examination of the data indicates that the interaction was due to the flattening of the curve for the experimental eye relative to the curve for the normal eye. This flattening was due to a floor effect created by the poor contrast sensitivity of the experimental eye. A two-tailed, paired t-test was done at each spatial frequency to compare the mean contrast sensitivities of the experimental and normal eyes. All six t-tests were significant and the t values ranged from 33.9 to 193.4 (df ¼ 6, po0.0005). Therefore, the contrast sensitivity of the experimental eye differed from that of the normal eye at all six spatial frequencies (Fig. 5).
Once again, the above-described preliminary (unpublished) data in glaucomatous rat stand in contrast to the published data from the primates. Primate glaucomatous eyes showed visual behavior changes where approximately 50% RGC have already died, but in glaucomatous rats the earliest changes in visual acuity were evident within a month following IOP elevation. It seems that about 15% RGC death was sufficient to measure the earliest changes in acuity and contrast
|
40 |
|
|
|
|
|
|
35 |
|
|
|
|
|
Sensitivity |
30 |
|
|
|
|
|
25 |
|
|
|
|
|
|
20 |
|
|
|
|
|
|
Contrast |
|
|
|
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
0 |
|
|
|
|
|
|
0.031 |
0.064 |
0.092 |
0.103 |
0.119 |
0.167 |
|
|
|
Spatial Frequency (c/d) |
|
|
|
Experimental Eye |
Control Eye |
Fig. 5. Changes in contrast sensitivity at six spatial frequencies of a glaucomatous eye when measured at 5 weeks after sustained elevation of IOP (25 mmHg).
488
sensitivity in the rat and these changes may be due to very sensitive measuring equipment.
Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
Dr. Yucel and his colleagues in Canada have shed light on the effects of elevated IOP in primate and human glaucomatous visual centers. Elevated IOP induces RGC death and as expected leads to the changes in the LGN where cell loss and the shrinkage of LGN was reported (Weber et al., 2000; Yucel et al., 2000, 2001, 2003). Finally, changes in the primary visual cortex were reported. Cytochrome oxidase activity decreased in the ocular dominant columns subserving the glaucomatous eye (Crawford et al., 2001; Lam et al., 2003). These transsynaptic changes in the visual pathways following glaucoma led the authors to describe glaucoma as a neurodegenerative disease. Evidence has further accumulated that IOP elevation induces changes in the LGN without optic nerve axonal loss. It is conceivable that initiating changes both physical (dendritic withdrawal preceding RGC death) and chemical (decrease in cytochrome oxidase activity in LGN) may be linked. Hence, one can conclude that initiation of the elevated IOP may trigger changes in the retina and CNS whose effect continues for a very long time. To date, emphasis has been placed on lowering IOP as a means to reduce RGC death in glaucomatous eyes. However, in many cases RGC death continues even after normal pressure is maintained.
Future directions
The continuous debate on the ‘‘dogma’’ of glaucoma, i.e., whether ganglion cells die first or optic axons are damaged first, is yet to be resolved. In both situations, changes commence in the termination sites of the visual pathways. The dramatic change seen in the visual centers in glaucomatous animal and human raise the question that the functional relationship between the loss or degradation of the visual field and the
changes in visual acuity and visual thresholds must be further explored.
The factors that initiate RGCs death in glaucoma are incompletely defined. Loss of RGCs via apoptotic mechanisms induced by the elevation of IOP leads to degenerative morphological changes and cell death in the LGN and primary visual cortex. Some reorganization of retinotopic cortical maps in adult mammals has been reported following lesions of the retina. Conditions that might lead to cortical neuroplasticity following IOP elevation in monkeys have been reported (Lam et al., 2003).
Rescued RGCs in the optic nerve transection model do not provide any means to assess their functionality, as cut optic axons do not regenerate ordinarily. Furthermore, rescued or still surviving and perhaps uninjured RGCs in glaucoma maintain their nerve connections to the brain centers allowing evaluations of their functionality. At what stage(s) in the progression of glaucomatous RGCs death is there degradation of the central visual field maps? It is important to acquire such information to allow better understanding of the progression of visual loss in glaucoma, and it will provide avenues to assess the effects of neuroprotective agents on the consequence of rescuing RGCs in glaucoma.
The ability of the neuronal system to undergo remodeling and repair following injury is influenced by interactions between the remaining viable RGCs in glaucomatous retina as well as by the response of individual cells to the reduction in IOP and the administration of neuroprotective agents. Another factor that ought to be considered is that the reduction in the overall number of RGC may induce the dendrodendritic interactions of the remaining RGCs in delimiting the size of the dendritic tree. If by reducing the IOP and/or administration of neuroprotective agents one can determine the functional consequences of retina leading to either partial or complete restitution of function, it may offer a new avenue for improving visual function in glaucoma patients.
Future experiments should be directed to explore the effect of lowering the IOP, either surgically or medically, on the receptive field sizes.
Is the degradation of visual receptive field ever restored? Experiments should also be directed to evaluate the progression of changes in visual function by recording from the visual cortex.
Is there functional reorganization in the primary visual cortex in response to glaucoma in human? If the emergence of degradation of visual fields takes a few months of sustained elevated IOP in rats and it happens when ganglion cell death cascade has slowed down, it might take much longer time in humans when IOP in glaucomatous eye has been managed.
Finally, as it is becoming acceptable that glaucomatous changes are well pronounced in central visual nuclei, the question arises that treating the visual centers by neuroprotective agents so that death of LGN and cortical neurons is reduced or controlled might benefit patients with glaucoma. Of course, these treatments should be coupled with lowering IOP treatments of the eye to have any real effect in glaucomatous patients.
Acknowledgment
The work reported has been supported by NIH/ NEI grants.
References
Ahmed, F.A., Chaudhary, P. and Sharma, S.C. (2001) Effects of increased intraocular pressure on rat retinal ganglion cells. Int. J. Dev. Neurosci., 19: 209–218.
Bahr, M., Wizenmann, A. and Thanos, S. (1992) Effect of bilateral tectum lesions on retinal ganglion cell morphology in rats. J. Comp. Neurol., 320: 370–380.
Baker, C.I., Peli, E., Knouf, N. and Kanwisher, N.G. (2005) Reorganization of visual processing in macular degeneration. J. Neurosci., 25: 614–618.
Berkelaar, M., Clarke, D.B., Wang, Y.C., Bray, G.M. and Aguayo, A.J. (1994) Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J. Neurosci., 14: 4368–4374.
Chaudhary, P. and Sharma, S.C. (2001) Apoptotic cell death following axotomy. In: Ingoglia N.A. and Murray M. (Eds.), Axonal Regeneration in the Central Nervous System. Marcel Dekker, New York, pp. 185–218.
Crawford, M.L., Harwerth, R.S., Smith, E.L., Mills, S. and Ewing, B. (2001) Experimental glaucoma in primates: changes in cytochrome oxidase blobs in V1 cortex. Invest. Ophthalmol. Vis. Sci., 42: 358–364.
489
Dreyer, E.B., Zurakowski, D., Schumer, R.A., Podos, S.M. and Lipton, S.A. (1996) Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol., 114: 299–305.
Duncan, R.O., Sample, P.A., Weinbel, R.W., Bowd, C. and Zangwill, L.M. (2007) Retinotopic organization of primary visual cortex in glaucoma: comparing fMRI measurements of cortical function with visual loss. Prog. Retin. Eye Res., 26: 38–56.
Eysel, U.T., Peichl, L. and Wassle, H. (1985) Dendritic plasticity in the early postnatal feline retina: quantitative characteristics and sensitive period. J. Comp. Neurol., 242: 134–145.
Flammer, J. and Drance, S.M. (1983) Reversibility of a glaucomatous visual field defect after acetazolamide therapy. Can. J. Ophthalmol., 18: 139–141.
Garcia-Valenzuela, E., Fahmey, A. and Sharma, S.C. (1993) Axotomy induces apoptotic cell death in adult retinal ganglion cells. Eur. J. Neurosci., (Suppl 6): p. 499.
Garcia-Valenzuela, E., Gorczyca, W., Darzynkiewicz, Z. and Sharma, S.C. (1994) Apoptosis in adult retinal ganglion cells after axotomy. J. Neurobiol., 25: 431–438.
Garcia-Valenzuela, E., Shareef, S., Walsh, J. and Sharma, S.C. (1995) Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res., 61: 33–44.
Garcia-Valenzuela, E. and Sharma, S.C. (1996) Optic nerve regeneration. In: Rich R., Shields B. and Krupin T. (Eds.), The Glaucomas. St. Louis, Mosby, pp. 199–212.
Greve, E.L., Dake, C.L. and Verduin, W.M. (1975) Proceedings: reversibility of visual field defects in glaucoma. Exp. Eye Res., 20: p. 183.
Grozdanic, S.D., Sakaguchi, D.S., Kwon, Y.H., Kardon, R.H. and Sonea, I.M. (2003) Functional characterization of retina and optic nerve after acute ocular ischemia in rats. Invest. Ophthalmol. Vis. Sci., 44: 2597–2605.
Jones, B.W., Watts, C.W. and Marc, R.E. (2005) Retinal remodelling. Clin. Exp. Optom., 88: 282–291.
King, W.M., Sarup, V., Sauve, Y., Carpenter, D.O. and Sharma, S.C. (2006) Expansion of visual receptive fields in experimental glaucoma. Vis. Neurosci., 23: 137–142.
Kirby, M.A. and Chalupa, L.M. (1986) Retinal crowding alters the morphology of alpha ganglion cells. J. Comp. Neurol., 251: 532–541.
Kolker, A.E. and Hetherington, J. (1983) Primary open-angle glaucoma. In: Mosby, C.V. (Ed.), Becker-Shafers Diagnosis and Therapy of the Glaucoma. St. Louis, Mosby, pp. 55–63.
Krueger-Naug, A.M., Emsley, J.G., Myers, T.L., Currie, R.W. and Clarke, D.B. (2003) Administration of brain-derived neurotrophic factor suppresses the expression of heat shock protein 27 in rat retinal ganglion cells following axotomy. Neuroscience, 116: 49–58.
Lam, D.Y., Kaufman, P.L. and Gabelt, B.T. (2003) Neurochemical correlates of cortical plasticity after unilateral elevated intraocular pressure in primate model of glaucoma. Invest. Ophthalmol. Vis. Sci., 44: 2573–2581.
Laquis, S., Chaudhary, P. and Sharma, S.C. (1998) The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res., 784: 100–104.
490
Leventhal, A.G., Schall, J.D. and Ault, S.J. (1988) Extrinsic determinants of retinal ganglion cell structure in the cat. J. Neurosci., 8(6): 2028–2038.
Levin, L.A. (2003) Retinal ganglion cells and neuroprotection for glaucoma. Surv. Ophthalmol., 48(1): S21–S24.
Levkovitch-Verbin, H., Quigley, H.A., Kerrigan-Baumrind, L.A., D’Anna, S.A., Kerrigan, D. and Pease, M.E. (2001) Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci., 42: 975–982.
Lewis, G.P., Linberg, K.A. and Fisher, S.K. (1998) Neurite outgrowth from bipolar and horizontal cells after experimental retinal detachment. Invest. Ophthalmol. Vis. Sci., 39: 424–434.
Liu, B. and Neufeld, A.H. (2001) Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch. Ophthalmol., 119: 240–245.
Marc, R.E., Jones, B.W. and Watt, C.B. (2006) Retinal remodeling: circuitry revision triggered by photoreceptor degeneration. In: Pinaud E., Tremere R. and De-Weerd E. (Eds.), Plasticity in the Visual System: From Genes to Circuits. Spring Science, New York.
Mey, J. and Thanos, S. (1993) Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res., 602: 304–317.
Morrison, J.C., Fraunfelder, F.W., Milne, S.T. and Moore, C.G. (1995) Limbal microvasculature of the rat eye. Invest. Ophthalmol. Vis. Sci., 36: 751–756.
Morrison, J.C., Moore, C.G., Deppmeier, L.M., Gold, B.G., Meshul, C.K. and Johnson, E.C. (1997) A rat model of chronic pressure-induced optic nerve damage. Exp. Eye Res., 64: 85–96.
Neufeld, A.H., Sawada, A. and Becker, B. (1999) Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. U.S.A., 96: 9944–9948.
Ngugen, T.H., Stievenart, J.L., Saucet, J.C., Gargasson, J.F., Cohen, Y.S., Pelegrini-Issac, M., Burnod, Y., Iba-Zizen, M.T. and Cabanis, E.A. (2004a) Cortical response to agerelated macular degeneration. Functional MRI study Part II. J. Fr. Ophtalmol., 27: 3572–3586.
Ngugen, T.H., Stievenart, J.L., Saucet, J.C., Gargasson, J.F., Cohen, Y.S., Pelegrini-Issac, M., Burnod, Y., Iba-Zizen, M.T. and Cabanis, E.A. (2004b) Cortical response to agerelated macular degeneration. Functional MRI study Part I. J. Fr. Ophtalmol., 27: 3565–3571.
Osborne, N.N., Chidlow, G., Layton, C.J., Wood, J.P., Casson, R.J. and Melena, J. (2004) Optic nerve and neuroprotection strategies. Eye, 18: 1075–1084.
Osborne, N.N., Ugarte, M., Chao, M., Chidlow, G., Bae, J.H., Wood, J.P. and Nash, M.S. (1999) Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol., 43(1): S102–S128.
Peichl, L. and Bolz, J. (1984) Kainic acid induces sprouting of retinal neurons. Science, 223: 503–504.
Peinado-Ramon, P., Salvador, M., Villegas-Perez, M.P. and Vidal-Sanz, M. (1996) Effects of axotomy and intraocular
administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Invest. Ophthalmol. Vis. Sci., 37: 489–500.
Prusky, G.T., Harker, K.T., Douglas, R.M. and Wishaw, I.Q. (2002) Variation in visual acuity within pigmented and nonpigmented and albino strains of rats. Behav. Brain Res., 136: 339–348.
Prusky, G.T., West, P.W. and Douglas, D.M. (2000) Behavioral assessment of visual acuity in mice and rats. Vision Res., 40: 2201–2209.
Quigley, H.A., Guy, J. and Anderson, D.R. (1979) Blockade of rapid axonal transport. Effect of intraocular pressure elevation in primate optic nerve. Arch. Ophthalmol., 97: 525–531.
Quigley, H.A. and Hohman, R.M. (1983) Laser energy levels for trabecular meshwork damage in the primate eye. Invest. Ophthalmol. Vis. Sci., 24: 1305–1307.
Quigley, H.A., Nickells, R.W., Kerrigan, L.A., Pease, M.E., Thibault, D.J. and Zack, D.J. (1995) Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci., 36: 774–786.
Rappaport, D.H. and Stone, J. (1983) Time course of morphological differentiation of cat retinal ganglion cells: influences on soma size. J. Comp. Neurol., 221: 42–52.
Rolando, M., Facino, M., Rathschuler, F., Bocca, L. and Zingirian, M. (1991) [Reversibility of visual field defects in primary open-angle glaucoma]. J. Fr. Ophtalmol., 14: 291–294.
Rousseau, V., Engelmann, R. and Sabel, B.A. (1999) Restoration of vision III: soma swelling dynamics predicts neuronal death or survival after optic nerve crush in vivo. Neuroreport, 10: 3387–3391.
Sauve, Y., Lu, B. and Lund, R.D. (2004) The relationship between full field electroretinogram and perimetry-like visual thresholds in RCS rats during photoreceptor degeneration and rescue by cell transplants. Vision Res., 44: 9–18.
Schmitt, U., Cross, R., Pazdernik, T.L. and Sabel, B.A. (1996) Loss and subsequent recovery of local cerebral glucose use in visual targets after controlled optic nerve crush in adult rats. Exp. Neurol., 13: 17–24.
Shareef, S., Sawada, A. and Neufeld, A.H. (1999) Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci., 40: 2884–2891.
Shareef, S.R., Garcia-Valenzuela, E., Salierno, A., Walsh, J. and Sharma, S.C. (1995) Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res., 61: 379–382.
Smith, E.L., Chino, Y.M., Harwerth, R.S., Ridder, R.S., Crawford, M.L.J. and DeSatnis, L. (1993) Retinal inputs to the monkey lateral geniculate nucleus in experimental glaucoma. Clin. Vis. Sci., 8: 113–139.
Tezel, G. and Yang, X. (2004) Caspase-independent component of retinal ganglion cell death, in vitro. Invest. Ophthalmol. Vis. Sci., 45: 4049–4059.
Urcola, J.H., Garcia, M., Hernandez, M. and Vecino, E. (2006) Three experimental glaucoma models in rats: comparison of
the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp. Eye Res., 83: 429–437.
van Adel, B.A., Kostic, C., Deglon, N., Ball, A.K. and Arsenijevic, Y. (2003) Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum. Gene Ther., 14: 103–115.
Weber, A.J., Chen, H., Hubbard, W.C. and Kaufman, P.L. (2000) Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest. Ophthalmol. Vis. Sci., 41: 1370–1379.
Weber, A.J. and Harman, C.D. (2005) Structure–function relations of parasol cells in the normal and glaucomatous primate retina. Invest. Ophthalmol. Vis. Sci., 46: 3197–3207.
Weber, A.J., Kaufman, P.L. and Hubbard, W.C. (1998) Morphology of single ganglion cells in the glaucomatous primate retina. Invest. Ophthalmol. Vis. Sci., 39: p. 2304.
Yan, Q., Wang, J., Matheson, C.R. and Urich, J.L. (1999) Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells
491
in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). J. Neurobiol., 38: 382–390.
Yoshikawa, K., Baba, H., Ochi, T., Inoue, T. and Inoue, Y. (1989) Reversibility of glaucomatous defects of the central visual field. Nippon Ganka Gakkai Zasshi, 93: 405–411.
Yucel, Y.H., Zhang, Q., Gupta, N., Kaufman, P.L. and Weinreb, R.N. (2000) Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch. Ophthalmol., 118: 378–384.
Yucel, Y.H., Zhang, Q., Weinreb, R.N., Kaufman, P.L. and Gupta, N. (2001) Atrophy of relay neurons in mangoand parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest. Ophthalmol. Vis. Sci., 42: 3216–3222.
Yucel, Y.H., Zhang, Q., Weinreb, R.N., Kaufman, P.L. and Gupta, N. (2003) Effects of retinal ganglion cell loss on mango-, parvo-, konicellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Porg. Retin. Eye Res., 22: 465–481.
